Immune System Disorder (Healthy Volunteers) Clinical Trial
Official title:
A Three-part, Sequential, Non-randomized, Open-label Study Designed to Evaluate the Effect of Oral Belumosudil on UGT1A1, P-gp, BCRP and OATP1B1 Inhibition in the Fed State in Healthy Male Subjects
The purpose of this study is to evaluate safety and pharmacokinetics (PK) effect of belumosudil on the uridine diphosphate glucuronosyltransferase (UGT)1A1 (Part 1), P glycoprotein (P-gp) (Part 2) and breast cancer resistance protein (BCRP)/organic anion transporting polypeptide (OATP)1B1 (Part 3) inhibition in the fed state in healthy male subjects.
Part 1: The estimated time from screening until the follow-up phone call is approximately 6 weeks per subject. Part 2: The estimated time from screening until the follow-up phone call is approximately 7 weeks per subject. Part 3: The estimated time from screening until the follow-up phone call is approximately 7 weeks per subjects. ;